Because we supposed that sensitive tumors would have both (1) characteristic tumor antigen presentation in the tumor-draining lymph nodes and (2) characteristic expression of CXCR3 ligands in tumors at baseline, we created a combined biomarker—the Antigen-Presentation-related gene expression and T-cells-attracting-related gene expression combined biomarker (AP/T score)—defined as the averaged expression of XCR1 and CXCR3 ligands. Here, CXCR3 is linked to neoplasm.